Tessin Biotechnology
Tessin Biotechnology, a leading name in the biopharmaceutical industry, is headquartered in China and operates extensively across Asia and Europe. Founded in 2015, the company has rapidly established itself as a pioneer in innovative biotechnological solutions, focusing on drug development and advanced therapeutic products. Tessin's core offerings include monoclonal antibodies and gene therapies, distinguished by their cutting-edge research and development processes. The company has achieved significant milestones, including successful clinical trials and partnerships with major healthcare institutions, solidifying its position in the competitive biotech landscape. With a commitment to enhancing patient outcomes, Tessin Biotechnology continues to push the boundaries of science, making notable contributions to the fields of oncology and rare diseases.
DitchCarbon Score
How does Tessin Biotechnology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tessin Biotechnology's score of 0 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tessin Biotechnology's reported carbon emissions
Tessin Biotechnology, headquartered in CN, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current impact on carbon emissions or their strategic approach to climate change. However, the absence of data may indicate an opportunity for the company to enhance transparency and set measurable targets in line with industry standards. As the biotechnology sector increasingly prioritises sustainability, Tessin Biotechnology may benefit from establishing clear climate commitments to align with global efforts in reducing greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tessin Biotechnology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
